Cellular viability effects of fatty acid amide hydrolase inhibition on cerebellar neurons
- PMID: 21854612
- PMCID: PMC3171300
- DOI: 10.1186/1755-7682-4-28
Cellular viability effects of fatty acid amide hydrolase inhibition on cerebellar neurons
Abstract
The endocannabinoid anandamide (ANA) participates in the control of cell death inducing the formation of apoptotic bodies and DNA fragmentation. The aim of this study was to evaluate whether the ANA degrading enzyme, the fatty acid amide hydrolase (FAAH), would induce cellular death. Experiments were performed in cerebellar granule neurons cultured with the FAAH inhibitor, URB597 (25, 50 or 100 nM) as well as endogenous lipids such as oleoylethanolamide (OEA) or palmitoylethanolamide (PEA) and cellular viability was determined by MTT test. Neurons cultured with URB597 (25, 50 or 100 nM) displayed a decrease in cellular viability. In addition, if cultured with OEA (25 nM) or PEA (100 nM), cellular death was found. These results further suggest that URB597, OEA or PEA promote cellular death.
Figures



Similar articles
-
Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety.Psychopharmacology (Berl). 2018 Nov;235(11):3211-3221. doi: 10.1007/s00213-018-5020-7. Epub 2018 Sep 24. Psychopharmacology (Berl). 2018. PMID: 30251159
-
Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats.PLoS One. 2011;6(7):e20766. doi: 10.1371/journal.pone.0020766. Epub 2011 Jul 14. PLoS One. 2011. PMID: 21779318 Free PMC article.
-
Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat.Eur J Pharmacol. 2007 May 7;562(1-2):82-91. doi: 10.1016/j.ejphar.2007.01.076. Epub 2007 Feb 8. Eur J Pharmacol. 2007. PMID: 17336288
-
Fatty acid amide hydrolase inhibitors--progress and potential.CNS Neurol Disord Drug Targets. 2011 Aug;10(5):545-58. doi: 10.2174/187152711796234989. CNS Neurol Disord Drug Targets. 2011. PMID: 21631410 Review.
-
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.Exp Neurol. 2010 Jul;224(1):48-55. doi: 10.1016/j.expneurol.2010.03.022. Epub 2010 Mar 29. Exp Neurol. 2010. PMID: 20353771 Review.
Cited by
-
The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial.BMC Endocr Disord. 2024 Oct 8;24(1):210. doi: 10.1186/s12902-024-01738-7. BMC Endocr Disord. 2024. PMID: 39379951 Free PMC article. Clinical Trial.
-
Oleoylethanolamide Supplementation Reduces Inflammation and Oxidative Stress in Obese People: A Clinical Trial.Adv Pharm Bull. 2018 Aug;8(3):479-487. doi: 10.15171/apb.2018.056. Epub 2018 Aug 29. Adv Pharm Bull. 2018. PMID: 30276145 Free PMC article.
-
OEA alleviates apoptosis in diabetic rats with myocardial ischemia/reperfusion injury by regulating the PI3K/Akt signaling pathway through activation of TRPV1.Front Pharmacol. 2022 Nov 14;13:964475. doi: 10.3389/fphar.2022.964475. eCollection 2022. Front Pharmacol. 2022. PMID: 36452230 Free PMC article.
References
-
- Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem. 1999;6(8):757–773. - PubMed
-
- Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G. et al.Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425(6953):90–93. doi: 10.1038/nature01921. - DOI - PubMed
LinkOut - more resources
Full Text Sources